Inventia Healthcare Limited Diltiazem Export Data — India (DGFT 2022–2026)

Name: Inventia Healthcare Limited Diltiazem Export Records India — #12 Exporter, 36 Shipments, $504.2K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-04-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Diltiazem

India Pharmaceutical Trade Intelligence

$18.0M184 Suppliers71 CountriesHS 30049079

ExportsIndia → UNITED STATES62.4%India → CANADA18.8%

ImportsUNITED KINGDOM → India$760.0K UNITED STATES → India$155.5K

#1 Supplier: EMCURE PHARMACEUTICALS #1 Buyer: EVERSANA LIFE

Inventia Healthcare Limited — Diltiazem Exporter #12 | $504.2K Trade Value | TransData Nexus | TransData Nexus

Inventia Healthcare Limited — Diltiazem Exporter Profile

Indian Pharmaceutical Exporter · #12 for Diltiazem · $504.2K export value · DGFT Verified

Inventia Healthcare Limited is the #12 Indian exporter of Diltiazem with $504.2K in export value and 36 verified shipments. Inventia Healthcare Limited holds a 2.8% market share in Diltiazem exports across 1 countries. The company exports 11 pharmaceutical products worth $36.5M across 6 therapeutic categories.

Inventia Healthcare Limited — Diltiazem Export Profile: Buyers & Destinations

Inventia Healthcare Limited Diltiazem export treemap — buyers and destination countries | TransData Nexus

Where Does India Export Diltiazem?

Country	Value	Shipments	Share
UNITED STATES	$10.3M	207	61.3%
CANADA	$3.4M	133	20.1%
SRI LANKA	$1.6M	85	9.4%
UNITED ARAB EMIRATES	$555.9K	206

Who Are the Top Buyers of Diltiazem from India?

Buyer	Country	Value	Orders
EVERSANA LIFE SCIENCE SERVICES	UNITED STATES	$2.3M	47
MARCAN PHARMACEUTICALS INC.	CANADA	$1.6M	57
TEVA PHARMACEUTICALS USA, INC	UNITED STATES	$1.4M	27
EVERSANA LIFE SCIENCES SERVICES,LLC	UNITED STATES	$1.1M	22
MARCAN PHARMACEUTICALS INC.,	CANADA	$1.0M	40
MARCAN PHARMACEUTICALS INC	CANADA	$700.5K	27
MYLAN PHARMACEUTICALS INC	UNITED STATES	$686.9K	18
EUGIA US LLC	UNITED STATES	$450.0K	9
EVERSANA LIFESCIENCE SERVICES	UNITED STATES	$400.0K	8
J. KNIPPER & COMPANY	UNITED STATES	$250.0K	5

India's Diltiazem is purchased by 298 buyers worldwide. The top buyer is EVERSANA LIFE SCIENCE SERVICES (UNITED STATES), followed by MARCAN PHARMACEUTICALS INC. and TEVA PHARMACEUTICALS USA, INC.

How Does Inventia Healthcare Limited Compare to Nearest Diltiazem Exporters?

Exporters ranked immediately above and below #12 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
7	EUGIA PHARMA SPECIALITIES LIMITED	$550.0K	11	1	$50.0K
10	ALTAIR LIFESCIENCE	$518.7K	97	1	$5.3K
12	INVENTIA HEALTHCARE LIMITED ★	$504.2K	36	1	$14.0K
13	TORRENT PHARMACEUTICALS LIMITED	$400.0K	8	1	$50.0K
11	ALEMBIC PHARMACEUTICALS LIMITED	$250.0K	5	1	$50.0K

Inventia Healthcare Limited ranks #12 among 184 Indian Diltiazem exporters. Average shipment value of $14.0K compared to the market average of $78.0K. The closest competitors by value are EUGIA PHARMA SPECIALITIES LIMITED and ALTAIR LIFESCIENCE.

Which Indian Ports Ship Diltiazem Exports?

Port	Shipments	% Share
SAHAR AIR	357	19.6%
SAHAR AIR CARGO ACC (INBOM4)	302	16.6%
DELHI AIR CARGO ACC (INDEL4)	201	11.0%
NHAVA SHEVA SEA (INNSA1)	181	9.9%
DELHI AIR	155	8.5%
Bombay Air	100	5.5%
JNPT/ NHAVA SHEVA SEA	52	2.9%
Delhi Air	36	2.0%

Geopolitical & Trade Policy Impact on Inventia Healthcare Limited's Diltiazem Exports

Inventia Healthcare's extensive export operations are currently navigating a complex geopolitical landscape that presents both challenges and opportunities. The ongoing Israel-Iran tensions have led to disruptions in Red Sea shipping routes, resulting in increased freight costs and extended transit times. These logistical challenges are particularly impactful for time-sensitive pharmaceutical shipments, necessitating strategic adjustments in supply chain management to mitigate potential delays and cost escalations. (pharmaceuticalcommerce.com)

In the United States, recent tariff implementations have introduced additional complexities for Indian pharmaceutical exporters. The imposition of tariffs on a broad range of imports, including pharmaceuticals, has raised concerns about cost competitiveness and market access. Companies like Inventia must navigate these policy shifts by exploring alternative markets and enhancing operational efficiencies to maintain their competitive edge. (apnews.com)

Conversely, the European Union's stringent regulatory frameworks, such as the Falsified Medicines Directive, necessitate rigorous compliance measures. While these regulations impose additional operational requirements, they also present an opportunity for companies with robust quality systems to differentiate themselves. Inventia's adherence to international quality standards positions it favorably to meet these regulatory demands and strengthen its presence in the European market.

Inventia Healthcare Limited — Regulatory Compliance & Quality Standards

The global pharmaceutical industry is witnessing heightened regulatory scrutiny, with agencies like the U.S. FDA and the European Medicines Agency intensifying their focus on manufacturing practices and product quality. For Indian exporters, this translates into the necessity for stringent compliance with Good Manufacturing Practices (GMP) and other regulatory standards.

Inventia Healthcare's manufacturing facility in Ambernath and its research and development center in Thane are accredited by the U.S. FDA, U.K. MHRA, and other stringent regulatory authorities. This compliance underscores the company's commitment to maintaining high-quality standards, facilitating access to both emerging and regulated markets. (platinumequity.com)

However, the broader Indian pharmaceutical sector faces challenges related to quality assurance, with instances of regulatory non-compliance affecting the industry's reputation. To mitigate these risks, companies like Inventia must continually invest in quality control systems, employee training, and process improvements to ensure sustained compliance and market trust.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Diltiazem shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Inventia Healthcare Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 71+ countries, 298+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Diltiazem

Diltiazem

Inventia Healthcare Limited — Diltiazem Exporter Profile

Inventia Healthcare Limited — Diltiazem Export Profile: Buyers & Destinations

Where Does India Export Diltiazem?

Who Are the Top Buyers of Diltiazem from India?

What Is India's Total Diltiazem Export Value and How Much Does Inventia Healthcare Limited Contribute?

What Is the Average Shipment Value for Inventia Healthcare Limited's Diltiazem Exports?

How Does Inventia Healthcare Limited Compare to Other Indian Diltiazem Exporters?

Regulatory Requirements: Exporting Diltiazem to Key Markets

United States — FDA

Canada — HC

How Does Inventia Healthcare Limited Compare to Nearest Diltiazem Exporters?

Which Indian Ports Ship Diltiazem Exports?

What Other Cardiovascular Products Does Inventia Healthcare Limited Export?

Geopolitical & Trade Policy Impact on Inventia Healthcare Limited's Diltiazem Exports

Inventia Healthcare Limited — Regulatory Compliance & Quality Standards

About Inventia Healthcare Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Diltiazem Export Data from Inventia Healthcare Limited

Diltiazem Stats

Company Overview

Top Products by Inventia Healthcare Limited

Related Analysis

Need Detailed Export Data?

Data Source